Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Optimizing platelet inhibition in clopidogrel poor metabolizers: therapeutic options and practical considerations.

Angiolillo DJ, Ueno M.

JACC Cardiovasc Interv. 2011 Apr;4(4):411-4. doi: 10.1016/j.jcin.2011.03.001. No abstract available.

2.

The influence of CYP2C19 polymorphisms on the pharmacokinetics, pharmacodynamics, and clinical effectiveness of P2Y(12) inhibitors.

Price MJ, Tantry US, Gurbel PA.

Rev Cardiovasc Med. 2011;12(1):1-12. doi: 10.3909/ricm0590. Review.

PMID:
21546883
3.

Proton pump inhibitors and clopidogrel.

Gaglia MA Jr, Waksman R.

Cardiovasc Ther. 2010 Jun;28(3):169-76. doi: 10.1111/j.1755-5922.2010.00143.x. Epub 2010 Mar 25. Review.

PMID:
20345494
4.

Pharmacogenetics of clopidogrel.

O'Connor SA, Hulot JS, Silvain J, Cayla G, Montalescot G, Collet JP.

Curr Pharm Des. 2012;18(33):5309-27. Review.

PMID:
22724417
5.

Bedside evaluation of thienopyridine antiplatelet therapy.

Price MJ.

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732. Review. No abstract available.

6.

[Pharmacogenetics of clopidogrel and its clinical significance].

Panchenko EP, Komarov AL.

Kardiologiia. 2012;52(9):44-52. Review. Russian.

PMID:
23098546
7.

Pharmacogenomics of clopidogrel: evidence and perspectives.

Yin T, Miyata T.

Thromb Res. 2011 Oct;128(4):307-16. doi: 10.1016/j.thromres.2011.04.010. Epub 2011 May 18. Review.

PMID:
21592545
8.

Clinical impact of genetically determined platelet reactivity.

Laine M, Arméro S, Peyrol M, Sbragia P, Thuny F, Paganelli F, Bonello L.

J Cardiovasc Transl Res. 2013 Jun;6(3):398-403. doi: 10.1007/s12265-012-9421-4. Epub 2012 Nov 13. Review.

PMID:
23149816
9.

Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, Roden DM, Klein TE, Shuldiner AR; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2011 Aug;90(2):328-32. doi: 10.1038/clpt.2011.132. Epub 2011 Jun 29. Review. No abstract available.

10.

[Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].

Kremneva LV, Shalaev SV.

Ter Arkh. 2008;80(12):89-95. Review. Russian. No abstract available.

PMID:
19227916
11.

[A current problem for regulators. Clopidogrel and pharmacokinetics].

Zündorf I, Dingermann T.

Pharm Unserer Zeit. 2009;38(4):360-7. doi: 10.1002/pauz.200900326. Review. German. No abstract available.

PMID:
19572363
12.

Clopidogrel resistance: pharmacokinetic or pharmacogenetic?

Ford NF.

J Clin Pharmacol. 2009 May;49(5):506-12. doi: 10.1177/0091270009332433. Epub 2009 Feb 26. Review.

PMID:
19246723
13.

Current evidence for genetic testing in clopidogrel-treated patients undergoing coronary stenting.

Sibbing D, Bernlochner I, Kastrati A, Paré G, Eikelboom JW.

Circ Cardiovasc Interv. 2011 Oct 1;4(5):505-13; discussion 513. doi: 10.1161/CIRCINTERVENTIONS.111.962183. Review. No abstract available.

14.

Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.

Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA.

Catheter Cardiovasc Interv. 2009 Jan 1;73(1):1-14. doi: 10.1002/ccd.21782. Review.

PMID:
19089929
15.

[New platelet P2Y12 inhibitors versus clopidogrel in percutaneous coronary interventions. a meta-analysis].

Preobrazhenskiĭ DV.

Kardiologiia. 2011;51(2):70-1. Review. Russian. No abstract available.

PMID:
21627602
16.

Antiplatelet therapy in percutaneous coronary intervention: recent advances in oral antiplatelet agents.

Wong YW, Prakash R, Chew DP.

Curr Opin Cardiol. 2010 Jul;25(4):305-11. doi: 10.1097/HCO.0b013e328339f1aa. Review.

PMID:
20421791
17.

Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention.

Uhry S, Bessereau J, Camoin-Jau L, Paganelli F, Bonello L.

Hosp Pract (1995). 2012 Apr;40(2):104-17. doi: 10.3810/hp.2012.04.976. Review.

PMID:
22615085
18.

Mechanisms of variability in antiplatelet agents response.

Cattaneo M.

Thromb Res. 2012 Oct;130 Suppl 1:S27-8. doi: 10.1016/j.thromres.2012.08.266. Review.

PMID:
23026654
19.

Personalized approaches to clopidogrel therapy: are we there yet?

Anderson CD, Biffi A, Greenberg SM, Rosand J.

Stroke. 2010 Dec;41(12):2997-3002. doi: 10.1161/STROKEAHA.110.594069. Epub 2010 Oct 28. Review.

20.

Clopidogrel pharmacogenomics: next steps: a clinical algorithm, gene-gene interactions, and an elusive outcomes trial.

Gladding P, Panattoni L, Webster M, Cho L, Ellis S.

JACC Cardiovasc Interv. 2010 Oct;3(10):995-1000. doi: 10.1016/j.jcin.2010.08.012. Review.

Items per page

Supplemental Content

Write to the Help Desk